Home/Tryptamine Therapeutics/Herwig Janssen

HJ

Herwig Janssen

Chairman, Board

Tryptamine Therapeutics

Therapeutic Areas

Neuropsychiatry Pain Gastroenterology Eating Disorders

Tryptamine Therapeutics Pipeline

Drug	Indication	Phase
TRP-8803	Fibromyalgia, IBS, Binge Eating Disorder, Depression, Pain, OCD	Phase 1

Leadership Team at Tryptamine Therapeutics

Robin Carhart-Harris, Ph.D.

Chairman, Scientific Advisory Board

Dr. Daniel Tillett

Non‑Executive Director

View full Tryptamine Therapeutics profile